Rajat Mohindra

5PUBLICATIONS
43CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Apr 21, 2026
Time-of-day of first checkpoint inhibitor dose influences clinical outcomes and immune responses in hepatocellular carcinoma.

|Nov 14, 2025
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart.

David F Lamparter, Virginia C Schmid, Rajat Mohindra

|Mar 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

|Apr 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.

Hannah Barman, Sriram Venkateswaran, Antonio Del Santo

Pageof 1

Frequent Collaborators

4 joint publications

G Scott Chandler

3 joint publications

Howard L Li

3 joint publications

Marina Barretti

3 joint publications

Christopher Thoburn